Although the human amniotic membrane (hAM) has been demonstrated to promote angiogenesis, its efficacy in healing ischemic wounds remains unknown. Therefore, the current study aimed to evaluate the potential of hAM as a dressing for treating ischemic wounds. The inferior abdominal wall arteries and veins of male rats were divided, and an ischemic wound was created on each side of the abdominal wall. Of the two ischemic wounds created, only one was covered with hAM, and its wound healing effect was determined by measuring the wound area. Angiogenesis was assessed by measuring microvessel density (MVD). On day 5, the mean wound area changed from 400 mm2 to 335.4 (260–450) mm2 in the hAM group and to 459 (306–570) mm2 in the control group (p = 0.0051). MVD was 19.0 (10.4–24.6) in the hAM group and 15.1 (10.6–20.8) in the control group (p = 0.0026). No significant differences in local pro- and anti-inflammatory cytokine levels were observed between the two groups. Histological examination revealed no rejection of the transplanted hAM. Therefore, the hAM may serve as a novel wound dressing that can promote angiogenesis and healing in ischemic wounds.
FarberA. Chronic limb-threatening ischemia. N Engl J Med2018; 379(2): 171–180.
2.
MillsJLConteMSArmstrongDG, et al.The Society for Vascular Surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg2014; 59(1): 220.
3.
SlimHTiwariAAhmedA, et al.Distal versus ultradistal bypass grafts: amputation-free survival and patency rates in patients with critical leg ischaemia. Eur J Vasc Endovasc Surg2011; 42(1): 83–88.
4.
IidaOSogaYHiranoK, et al.Midterm outcomes and risk stratification after endovascular therapy for patients with critical limb ischaemia due to isolated below-the-knee lesions. Eur J Vasc Endovasc Surg2012; 43(3): 313–321.
5.
NorgrenLHiattWRDormandyJA, et al.Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg2007; 45(1): S5–S67.
6.
BeckerFRobert-EbadiHRiccoJB, et al.Chapter I: definitions, epidemiology, clinical presentation and prognosis. Eur J Vasc Endovasc Surg2011; 42Suppl 2: S4–S12.
7.
Abu DabrhAMSteffenMWUndavalliC, et al.The natural history of untreated severe or critical limb ischemia. J Vasc Surg2015; 62(6): 1642–1651.
8.
MiyaharaTSuharaMNemotoY, et al.Long-term results of treatment for critical limb ischemia. Ann Vasc Dis2015; 8: 192–197.
9.
UmezawaAHasegawaAInoueM, et al.Amnion-derived cells as a reliable resource for next-generation regenerative medicine. Placenta2019; 84: 50–56.
10.
KoobTJRennertRZabekN, et al.Biological properties of dehydrated human amnion/chorion composite graft: implications for chronic wound healing. Int Wound J2013; 10(5): 493–500.
11.
HuangGJiSLuoP, et al.Accelerated expansion of epidermal keratinocyte and improved dermal reconstruction achieved by engineered amniotic membrane. Cell Transplant2013; 22(10): 1831–1844.
12.
Mahmoudi-RadMAbolhasaniEMoravvejH, et al.Acellular amniotic membrane: an appropriate scaffold for fibroblast proliferation. Clin Exp Dermatol2013; 38(6): 646–651.
13.
BuhimschiIAJabrMBuhimschiCS, et al.The novel antimicrobial peptide beta3-defensin is produced by the amnion: a possible role of the fetal membranes in innate immunity of the amniotic cavity. Am J Obstet Gynecol2004; 191(5): 1678–1687.
14.
FranzMGPayneWGXingL, et al.The use of amnion-derived cellular cytokine solution to improve healing in acute and chronic wound models. Eplasty2008; 8: e21.
15.
PayneWGWachtelTLSmithCA, et al.Effect of amnion-derived cellular cytokine solution on healing of experimental partial-thickness burns. World J Surg2010; 34(7): 1663–1668.
16.
KoganSSoodAGranickMS. Amniotic membrane adjuncts and clinical applications in wound healing: a review of the literature. Wounds2018; 30(6): 168–173.
17.
HofmannATNeumannSFergusonJ, et al.* A rodent excision model for ischemia-impaired wound healing. Tissue Eng C Methods2017; 23(12): 995–1002.
18.
KestingMRWolffKDHohlweg-MajertB, et al.The role of allogenic amniotic membrane in burn treatment. J Burn Care Res2008; 29(6): 907–916.
19.
DoucetteMPayneKMLoughW, et al.Early advanced therapy for diabetic foot ulcers in high amputation risk veterans: a cohort study. Int J Low Extrem Wounds2022; 21(2): 111–119.
20.
TettelbachWCazzellSReyzelmanAM, et al.A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers: a prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics. Int Wound J2019; 16(1): 19–29.
21.
DuaHSGomesJAPKingAJ, et al.The amniotic membrane in ophthalmology. Surv Ophthalmol2004; 49(1): 51–77.
22.
RazzaghiMRahavianAFallahKM, et al.Use of human amniotic membrane repair of anterior urethral defect: first clinical report. Int J Urol Off J Jpn Urol Assoc2020; 27(7): 605–609.
23.
CheungCYSinghMEbaughMJ, et al.Vascular endothelial growth factor gene expression in ovine placenta and fetal membranes. Am J Obstet Gynecol1995; 173(3): 753–759.
24.
AbidiaALadenGKuhanG, et al.The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial. Eur J Vasc Endovasc Surg2003; 25(6): 513–518.
25.
ShinsatoTMiyataMKubozonoT, et al.Waon therapy mobilizes CD34+ cells and improves peripheral arterial disease. J Cardiol2010; 56(3): 361–366.
26.
SunHCTangZYLiXM, et al.Microvessel density of hepatocellular carcinoma: its relationship with prognosis. J Cancer Res Clin Oncol1999; 125(7): 419–426.
27.
WangWQLiuLXuHX, et al.Intratumoral α-SMA enhances the prognostic potency of CD34 associated with maintenance of microvessel integrity in hepatocellular carcinoma and pancreatic cancer. PLoS One2013; 8(8): e71189.
28.
SinghRChouhanUSPurohitS, et al.Radiation processed amniotic membranes in the treatment of non-healing ulcers of different etiologies. Cell Tissue Bank2004; 5(2): 129–134.
29.
Tateishi-YuyamaEMatsubaraHMuroharaT, et al.Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet Lond Engl2002; 360(9331): 427–435.
30.
TeiCShinsatoTMiyataM, et al.Waon therapy improves peripheral arterial disease. J Am Coll Cardiol2007; 50(22): 2169–2171.
31.
KuboMSonodaYMuramatsuR, et al.Immunogenicity of human amniotic membrane in experimental xenotransplantation. Invest Ophthalmol Vis Sci2001; 42(7): 1539–1546.
32.
Sant’AnnaLBCargnoniAResselL, et al.Amniotic membrane application reduces liver fibrosis in a bile duct ligation rat model. Cell Transplant2011; 20(3): 441–453.
33.
PratamaGVaghjianiVTeeJY, et al.Changes in culture expanded human amniotic epithelial cells: implications for potential therapeutic applications. PLoS One2011; 6(11): e26136.
34.
KjaergaardNHeinMHyttelL, et al.Antibacterial properties of human amnion and chorion in vitro. Eur J Obstet Gynecol Reprod Biol2001; 94(2): 224–229.
35.
RamutaTŽStarčič ErjavecMKreftME. Amniotic membrane preparation crucially affects its broad-spectrum activity against uropathogenic bacteria. Front Microbiol2020; 11: 469.
